CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials
China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...
Drug
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...
SciClone’s Danyelza Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that SciClone Pharmaceuticals Inc’s (Nasdaq: SCLN) Danyelza...
Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study
AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the...
MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe
Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...
Beijing Wantai’s Nasal Spray COVID-19 Vaccine Approved for Emergency Use in China
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced the inclusion of its...
Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...
WestVac Biopharma’s Recombinant COVID-19 Vaccine Approved for Emergency Use in China
Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells)...
Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study
China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...
Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program
China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine...
Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...
Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia
A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...
Hansoh’s EGFR Inhibitor Ameile Filed for EMA Review by Partner EQRx
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a market filing for its...
Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program
China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...
Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...
Innovent Biologics Doses First Volunteer in Orismilast Phase I Study
China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
NMPA Approves Henlius’ HLX04 Biosimilar for Lung and Colorectal Cancer
The National Medical Products Administration (NMPA) website indicates that China-based Shanghai Henlius Biotech’s (HKG: 2696)...